LR19125
NSCLC
Pre-clinicalActive
Key Facts
About AVEO Oncology
AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.
View full company profileTherapeutic Areas
Other NSCLC Drugs
| Drug | Company | Phase |
|---|---|---|
| REQORSA | Genprex | Phase 1/2 |
| HBM7008 | Harbour BioMed | Phase 1 |
| HBM7004 | Harbour BioMed | Discovery |
| TJ108 | Phrontline Biopharma | IND-enabling |
| MET FISH CDx | Amoy Diagnostics | Commercial |